ArticleAntonie van Leeuwenhoek2025
Insights into genetic heterogeneity and drug resistance in Leishmania donovani of the Indian sub-continent from genomic data.
Article in Antonie van Leeuwenhoek, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is one of the neglected tropical diseases that is endemic to over 90 countries, and its cases are being reported from non-endemic countries as well, like Austria. The cases of visceral leishmaniasis, caused by Leishmania donovani are concentrated on the Indian Subcontinent. There are several studies on the genetic heterogeneity, aneuploidy, and drug resistance emergence from Indian subcontinent as well as globally. However, no research has yet inspected the genomic data from the Indian subcontinent to conduct a comprehensive investigation at the nucleotide level of the genome. We have considered whole-genome sequence data from the publicly available database, i.e., European Nucleotide Archive. Genetic analysis has shown that there is tetraploidy in chromosome 31, trisomy in chromosomes 2 and 8, and trisomy was observed a in chromosomes 6 and 15 among some samples. This aneuploidy pattern is evolving over time as observed in the present study. The paromomycin drug has induced trisomy in chromosome 2. The pattern of aneuploidy variations in samples from the Indian subcontinent differs markedly from that in other continent's samples. Further, ATP-binding cassette family, Amastin-like surface proteins, A2 genes, amino acid permeases, heat shock 70-related protein 1, mitochondrial precursor, putative, partial and sodium stibogluconate resistance protein, putative proteins were those that exhibited the maximum number of mutations amid all the analyzed samples. The proteins showing higher number of mutations belong to membrane proteins that are involved in drug resistance mechanism. Most of these proteins are involved in the virulence and drug resistant mechanism (like transporter proteins). The present study provides the possible candidates which can be targeted to disarm the virulence of the protozoan and drug candidates for therapeutic interventions.
Indexed as
Identifiers
41258266What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.